Hepatect (Human Hepatitis B Immunoglobulin)

Hepatect is indicated for specific clinical situations where passive hepatitis B immunity is required.

• Prevention of hepatitis B infection after known or suspected exposure to hepatitis B virus.
• Prophylaxis of hepatitis B recurrence in patients undergoing liver transplantation.
• Supplementation of hepatitis B immune globulin in individuals with inadequate vaccine response.
• Use in combination with hepatitis B vaccine for enhanced protection in high‑risk settings.
• Administration to newborns of hepatitis B‑positive mothers to prevent perinatal transmission.

Side effects of Hepatect may vary in frequency and severity.

Common

• Mild fever or chills during or after infusion.
• Localized pain, redness, or swelling at the injection site.
• Headache or fatigue.
• Nausea or mild gastrointestinal discomfort.
• Transient elevation of liver enzymes.

Serious

• Severe allergic reaction (anaphylaxis) with rash, wheezing, or hypotension.
• Acute hemolysis or hemolytic anemia.
• Renal impairment or acute kidney injury.
• Thromboembolic events such as deep vein thrombosis.
• Severe thrombocytopenia or bleeding disorders.

When prescribing or administering Hepatect, several precautions should be observed.

• Assess patient history for prior hypersensitivity to human immunoglobulins or blood products.
• Monitor vital signs and for signs of anaphylaxis during the initial infusion.
• Use caution in patients with renal insufficiency; adjust infusion rate as needed.
• Evaluate liver function tests before and after administration, especially in transplant recipients.
• Avoid use in individuals with known IgA deficiency who have anti‑IgA antibodies.
• Document hepatitis B surface antigen status and prior vaccination history.
• Ensure proper aseptic technique to prevent contamination of the injectable solution.

Hepatect may interact with other medications or clinical conditions.

Avoid

• Concurrent administration of other blood‑derived products without appropriate monitoring.
• Use with live attenuated vaccines during the same infusion period.

Use with caution

• Immunosuppressive agents (e.g., corticosteroids, calcineurin inhibitors) as they may alter immune response.
• Anticoagulants, because infusion may affect coagulation parameters.
• Nephrotoxic drugs, given potential renal effects.
• Hepatotoxic medications, due to overlapping liver safety concerns.
• Agents that may cause hypersensitivity reactions, requiring close observation.